In what way does lipitor influence lipid protein uptake?

How does Lipitor affect LDL receptor activity?

Lipitor (atorvastatin) increases the number of LDL receptors on liver cells by inhibiting HMG-CoA reductase, the enzyme that limits cholesterol synthesis. With less cholesterol made inside the liver, the cells up-regulate LDL receptors, pulling more LDL particles out of the blood and lowering circulating LDL cholesterol.

What happens to VLDL and triglyceride clearance?

The same receptor increase also speeds removal of VLDL remnants because they contain apolipoprotein E, which the LDL receptor recognizes. As a result, triglyceride levels often fall 20–40 % in patients taking atorvastatin.

Can Lipitor change how HDL particles are handled?

Atorvastatin modestly raises HDL cholesterol in many patients, partly by reducing the exchange of cholesterol esters from HDL to LDL and VLDL particles. Direct uptake of HDL by scavenger receptor B1 is not strongly altered by the drug.

Does the effect depend on dose or duration?

Receptor up-regulation begins within days and plateaus within two to four weeks. Higher doses produce greater receptor expression and larger LDL reductions, but the relationship is not strictly linear because of feedback limits on receptor synthesis.

Are there differences compared with other statins?

All statins share the core mechanism of LDL-receptor up-regulation, yet atorvastatin tends to produce larger absolute LDL drops at equivalent doses because of its longer half-life and higher hepatic uptake. Comparative trials show roughly 5–10 % extra LDL reduction versus simvastatin or pravastatin at matched intensities.

When do patents and exclusivity end for atorvastatin?

The key composition-of-matter patent expired in 2011, opening the market to generics. Secondary patents on specific formulations have also lapsed, so multiple manufacturers now supply atorvastatin worldwide.